Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room

NCT ID: NCT01091337

Last Updated: 2010-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 96 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-05-31
• Study Completion Date: 2009-09-30

Brief Summary

To compare the efficacy and safety of inhaled procaterol (Meptin Air) versus inhaled salbutamol as metered dose inhaler (MDI) reliever of acute exacerbation of asthma not in imminent respiratory failure.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Procaterol

Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes

+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Group Type: EXPERIMENTAL

Procaterol

Intervention Type: DRUG

Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes

+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Salbutamol

Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Group Type: ACTIVE_COMPARATOR

Salbutamol

Intervention Type: DRUG

Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Interventions

Procaterol

Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes

+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Intervention Type: DRUG

Salbutamol

Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Intervention Type: DRUG

Other Intervention Names

Meptin Air; Ventolin Inhaler

Eligibility Criteria

Inclusion Criteria

• Adult patients aged 20 years old and above who are brought to the Emergency Room (ER) with acute bronchospasm
• Diagnosed cases of bronchial asthma based on history, physical examination and pulmonary function test
• Patients maintained on inhaled steroids who have no active medical problems (such as pulmonary TB, cardiac and renal diseases) aside from asthma
• Presence of known risk factors for asthma mortality does not disqualify patients from the study unless they are in impending respiratory failure
• All patients must sign the informed consent form

Exclusion Criteria

• Patients who are in respiratory distress consistent with severe exacerbation requiring intensive care hospital admission
• Who had intake of oral bronchodilator 6 hrs prior to consult
• Who had intake of oral steroids within the last 24 hrs
• Those with positive history of allergy and hypersensitivity to procaterol and salbutamol
• Patients who are diagnosed or clinically suspected to have COPD (ever-smokers with >10 pack-years smoking history or those exposed to workplaces where there is a heavy smoke load)
• Presence of concurrent disease/diseases that may aggravate asthma thereby delaying bronchodilator response (e.g., pneumonia, pulmonary congestion and others)
• Patients with other medical conditions which are serious enough to warrant immediate concurrent therapy during the 1 hour study and/or whose condition can be adversely affected by the treatment given (like uncontrolled diabetes, renal failure and hepatic insufficiency)
• The NIH Working Group on Asthma and Pregnancy has recommended that pregnant asthmatics are treated as aggressively as non-pregnant patients particularly during acute asthmatic attack. , Bronchodilators (except for epinephrine which is not in this study) have been found safe in pregnancy with a risk class of B and C. For these reasons, pregnancy by itself is not an exclusion criterion in this study and a pregnancy test will not be required for those who are in the childbearing age group. Requiring the test will unnecessarily delay the treatment for acute asthma. However, those who are suspected to be suffering from pregnancy-related complications like vaginal bleeding, premature labor, pre-eclampsia and others, are excluded.
• Severe Acute Asthma Attack, a reason for patient exclusion, shall be defined in this study as the presence of any one of the following criteria:

1. Severe asthma with a lack of response to initial therapy in the emergency department or worsening asthma despite adequate therapy.

2. Presence of confusion, drowsiness, other signs of impending respiratory arrest, or loss of consciousness

3. Wood-Downe's clinical asthma scoring score of >5 (see table 2 below)

• Any patient who is currently participating in other drug trials and/or having participated in other drug trials for less than 1 month of termination of the trial are excluded
• Patients who have previously participated in this study are excluded

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Otsuka Pharmaceutical, Inc., Philippines

INDUSTRY

Sponsor Role: lead

Responsible Party

Philippine General Hospital

Principal Investigators

Camilo Roa, MD

Role: PRINCIPAL_INVESTIGATOR

Philippine General Hospital

Locations

Philippine General Hospital

Manila, , Philippines

Countries

Philippines

Other Identifiers

KOIAA-MPT-2005-01

Identifier Type: -

Identifier Source: org_study_id